SYNCOMF — Syncom Formulations (India) Share Price
0.000.00%
Last trade - 00:00- IN₹14.38bn
- IN₹13.75bn
- IN₹2.63bn
- 67
- 12
- 69
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.21 | ||
| Price to Tang. Book | 4.21 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.6 | ||
| EV to EBITDA | 38.77 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.35% | ||
| Return on Equity | 9.3% | ||
| Operating Margin | 9.45% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 2,055.11 | 2,448.05 | 2,196.63 | 2,242.54 | 2,633.87 | n/a | n/a | 7.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +28.91 | +101.51 | -38.64 | +0.31 | +49.79 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. It is also engaged in the renting of properties. It manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.
Directors
- Kedarmal Bankda CHM (60)
- Ankit Bankda CFO
- Prachi Jain CCO
- Vijay Bankda MDR (53)
- Rinki Bankda EDR (30)
- Praveen Jindal NID (28)
- Vinod Kabra NID (60)
- Krishna Neema NID (60)
- Last Annual
- March 31st, 2024
- Last Interim
- March 31st, 2024
- Incorporated
- June 21st, 1988
- Public Since
- January 24th, 1994
- No. of Employees
- 799
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 940,000,000
- Address
- 207, Saket Nagar, INDORE, 452018
- Web
- https://syncomformulations.com/
- Phone
- +91 7312700458
- Auditors
- Sanjay Mehta & Associates
Upcoming Events for SYNCOMF
Syncom Formulations (India) Ltd Annual Shareholders Meeting
Q2 2025 Syncom Formulations (India) Ltd Earnings Release
Similar to SYNCOMF
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Syncom Formulations (India) share price?
As of Today at 11:36 UTC, shares in Syncom Formulations (India) are trading at IN₹12.89. This share price information is delayed by 15 minutes.
How has the Syncom Formulations (India) share price performed this year?
Shares in Syncom Formulations (India) last closed at IN₹12.89 and the price had moved by +69.61% over the past 365 days. In terms of relative price strength the Syncom Formulations (India) share price has outperformed the S&P BSE 100 Index by +29.6% over the past year.
What are the analyst and broker recommendations for Syncom Formulations (India)?
There is no consensus recommendation for this security.
What is the Syncom Formulations (India) dividend yield?
Syncom Formulations (India) does not currently pay a dividend.
Does Syncom Formulations (India) pay a dividend?
Syncom Formulations (India) does not currently pay a dividend.
When does Syncom Formulations (India) next pay dividends?
Syncom Formulations (India) does not currently pay a dividend.
How do I buy Syncom Formulations (India) shares?
To buy shares in Syncom Formulations (India) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Syncom Formulations (India)?
As of the previous close price of IN₹12.89, shares in Syncom Formulations (India) had a market capitalisation of IN₹12.12bn.
Where are Syncom Formulations (India) shares listed?
Here are the trading details for Syncom Formulations (India):
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SYNCOMF
What kind of share is Syncom Formulations (India)?
Based on an overall assessment of its quality, value and momentum Syncom Formulations (India) is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Syncom Formulations (India) share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Syncom Formulations (India) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Syncom Formulations (India). Over the past six months, its share price has underperformed the S&P BSE 100 Index by -24.18%.
As of the last closing price of IN₹12.89, shares in Syncom Formulations (India) were trading +4.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Syncom Formulations (India) PE Ratio?
The Syncom Formulations (India) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹12.89.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Syncom Formulations (India)?
Syncom Formulations (India)'s management team is headed by:
- Kedarmal Bankda - CHM
- Ankit Bankda - CFO
- Prachi Jain - CCO
- Vijay Bankda - MDR
- Rinki Bankda - EDR
- Praveen Jindal - NID
- Vinod Kabra - NID
- Krishna Neema - NID